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Abstract 
Background: To investigate whether pretreatment with dexmedetomidine (Dex) has a protective effect against 
acute lung injury (ALI) in an orthotopic autologous liver transplantation (OALT) rat model and to explore the mecha-
nisms responsible for the protective effect of Dex against lung injury.
Methods: Forty-eight rats underwent OALT and were randomly divided into six groups (n = 8 in each group) that 
received 10 µg/kg Dex, 50 µg/kg Dex, 50 µg/kg Dex + nonspecific α2-adrenergic receptor (AR) antagonist atipam-
ezole, 50 µg/kg Dex + specific α2B/C-AR antagonist ARC-239, 50 µg/kg Dex + specific α2A-AR antagonist BRL-44408, or 
the same amount of normal saline. The sham rats (n = 8) underwent anesthesia induction, laparotomy, and separa-
tion of the portal vein without liver ischemia and reperfusion. Lung tissue sections were stained with hematoxylin 
and eosin (HE) to visualize the damage. The expression of Toll-like receptor 4 (TLR4) and the phospho-nuclear factor 
(NF)-κB p65 subunit as well as inflammatory cytokines was measured.
Results: Rats exhibited increased histological lung injury scores and pulmonary edema following OALT. Pretreat-
ment with 50 μg/kg Dex attenuated OALT-induced lung injury in rats, probably by inhibiting the activation of the 
TLR4–NF-κB signaling pathway. The protective effect of Dex could be blocked by atipamezole or BRL-44408, but not 
by ARC-239, suggesting these effects of Dex were mediated, at least in part, by the α2A-AR.
Conclusions: Dex exerts protective effects against ALI following OALT, and this protection is associated with the sup-
pression of TLR4–NF-κB signaling. Thus, pretreatment with Dex may be a useful method for reducing lung damage 
caused by liver transplantation.
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Background
Acute lung injury (ALI) is a common complication fol-
lowing liver transplantation, with an incidence between 
34.2 and 77.8% [1, 2]. ALI is a progressive, devastating 
disease characterized by bilateral lung infiltration, 
hypoxemia refractory to oxygen therapy, and decreased 
lung compliance. Patients who develop ALI may further 
develop acute respiratory distress syndrome (ARDS), 
which has become one of the major causes of death after 
liver transplantation [3, 4]. Therefore, treatment strate-
gies to protect against ALI after liver transplantation 
have been studied.
Toll-like receptor 4 (TLR4) is a member of the TLR 
family that plays a key role in both innate and adaptive 
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immune responses. Triggering of the TLR pathway leads 
to activation of nuclear factor kappa B (NF-κB) and sub-
sequent regulation of immune and inflammatory genes/
factors, such as tumor necrosis factor (TNF)-α, interleu-
kin (IL)-1, IL-6, and IL-8 [5–7]. Previous studies revealed 
increased expression of TLR4 in peripheral blood mono-
nuclear cells and pro-inflammatory cytokines during the 
perioperative period of liver transplantation, indicating 
the involvement of TLR4 signaling in the development of 
ALI after liver transplantation [3, 8].
The alpha 2 adrenergic receptor (α2-AR) is a pro-
totypical G protein-coupled receptor (GPCR). α2-AR 
mediates the physiological and pharmacological actions 
of catecholamines via G-proteins to a variety of effec-
tors, including adenylyl cyclases and ion channels [9, 
10]. The α2-AR subfamily includes three different sub-
types (α2A, α2B, and α2C) in mammals, and they are found 
ubiquitously in vital organs and blood vessels [11, 12]. 
Dexmedetomidine (Dex) is a potent agonist for all three 
subtypes of human α2-ARs, having sedative, analgesic, 
and anti-sympathetic effects [11]. Dex has been shown to 
provide good perioperative hemodynamic stability and 
to have a protective effect on specific organs, including 
the heart, brain, and kidney, probably via decreasing cell 
apoptosis in a Bax/Bcl-2-related manner [13] and inhibit-
ing pro-inflammatory cytokine release [14–16].
To date, few studies have examined the protective 
effects of Dex against perioperative ALI after liver trans-
plantation. Our study aimed to investigate whether pre-
treatment with Dex resulted in a protective effect against 
ALI in an orthotopic autologous liver transplantation 
(OALT) rat model and to explore the underlying mecha-
nisms of this protective effect.
Methods
Animals
Male Sprague–Dawley rats (aged 8–10  weeks, weighing 
220–250  g) were purchased from the Medical Experi-
mental Animal Center of Guangdong Province, China. 
The study was conducted in accordance with the Guide 
for the Care and Use of Laboratory Animals (National 
Institutes of Health, 1985) [17] and was approved by the 
local Ethical Committee of the Third Affiliated Hospital, 
Sun Yat-Sen University.
Preparation of experimental animal models
The rats were kept under observation in a constant 
environment (room temperature 25–27°C) for 1  week 
prior to the start of the experiments. The OALT model 
was established in Sprague–Dawley rats as previously 
reported [18]. Briefly, under anesthesia, the falciform 
ligament of the liver of the rat was severed. The first 
hepatic portal was dissected, and the portal vein (PV) 
was liberated. The hepatic artery and biliary tract were 
liberated together based on their anatomic relationship. 
Vascular clamps were applied at the convergence of the 
inferior mesenteric, splenic veins, hepatic artery, supra 
hepatic vena cava (SVC), and inferior vena cava (IVC). 
The PV was punctured with a needle in preparation for 
reperfusion using pre-cooled Ringer lactate solution. 
Finally, the needle was extracted, and the PV, SVC, IVC, 
and hepatic artery were unclamped. All rats were sacri-
ficed 8  h after liver reperfusion for collection of blood 
and lung samples.
Grouping and drug treatment
Forty-eight rats subjected to OALT were randomly 
divided into six groups (n  =  8 in each group) that 
received 10 µg/kg Dex (group D1), 50 µg/kg Dex (group 
D2), 50  µg/kg Dex  +  nonspecific α2-AR antagonist ati-
pamezole (group B1), 50 µg/kg Dex +  specific α2B/C-AR 
antagonist ARC-239 (group B2), 50  µg/kg Dex  +  spe-
cific α2A-AR antagonist BRL-44408 (group B3), or the 
same amount of normal saline (model group or group 
M) [19]. The rats were intraperitoneally injected with 
Dex at different doses 30 min before OALT, and 500 µg/
kg atipamezole, 1.5 mg/kg BRL-44408, or 50 µg/kg ARC-
239 40 min before OALT, according to the group desig-
nations. The dose selection of antagonists was based on 
the antagonists’ affinity and dose–effect relationship with 
Dex. The sham rats (n = 8; the sham group or group S) 
underwent anesthesia induction, laparotomy, and sepa-
ration of the portal vein without liver ischemia and 
reperfusion.
Histological analysis of lung tissues
Lung tissues were fixed, sectioned at 4 μm thickness, and 
stained with hematoxylin and eosin (HE). The sections 
were scored as previously reported, and the histological 
scoring parameters included edema of the alveoli, edema 
of the alveolar mesenchyme, intra-alveolar cell infiltra-
tion, alveolar hemorrhage, and atelectasis [18].
Lung wet‑to‑dry (W/D) weight ratio
The wet (W) and dry (D) weights (after drying in venti-
lated oven at 80°C for 24 h) of the right middle lung lobes 
were measured. The lung W/D weight ratio was calcu-
lated by dividing the wet weight by the dry weight.
Western blotting analysis of TLR4 expression
Protein samples were extracted from the lung tissues. 
Samples (20 μg protein) were loaded onto a 10% sodium 
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE) gel and then transferred onto a polyvinylidene 
difluoride (PVDF) membrane. The membrane was 
blocked with 5% fat-free in Tris-buffered saline-Tween 
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(TBS-T) blocking solution (containing 0.2% Tween-20, 
20 mmol/L Tris–HCl, and 150 mmol/L NaCl, pH 7.14) at 
37°C for 1 h, followed by incubation with primary anti-
body (1:1,000; Abcam, USA) at 37°C for 2 h. Membranes 
were washed with TBS solution containing 1% milk four 
times and then incubated at room temperature for 1  h 
with horseradish peroxidase (HRP)-conjugated second-
ary antibody (dilution 1:2,000, Santa Cruz Biotechnology, 
CA, USA). The bands on the membranes were visualized 
by an enhanced chemiluminescence (ECL) system. The 
density of each band was quantified by an image analyzer 
(Lab Works Software, CA, USA) and corrected by refer-
ence to the expression value for glyceraldehyde-3-phos-
phate dehydrogenase (GAPDH).
Immunofluorescent assay and laser scanning confocal 
microscopy (LSCM)
Paraffin-embedded sections of lung tissue were dewaxed 
and rehydrated. Antigen retrieval was performed by heat-
ing in citrate buffer (pH = 6.0). Then, the sections were 
treated with 3% hydrogen peroxide (H2O2) for 10  min 
and incubated with a primary rabbit phospho-NF-κB p65 
antibody (Cell Signaling Technology, MA, USA) at a dilu-
tion of 1:100, overnight at 4°C. The sections were washed 
with phosphate-buffered saline (PBS) and then further 
incubated with a fluorescein isothiocyanate (FITC)-con-
jugated goat anti-rabbit secondary antibody at a dilution 
of 1:100 (Life Technologies, USA) for 2  h at room tem-
perature in the dark. The sections were counterstained 
with 4,6-diamidino-2-phenylindole (DAPI) to visualize 
nuclei. Images were captured by LSCM (Zeiss LSM 510 
META, Jena, Germany).
Enzyme‑linked immunosorbent assay (ELISA)
The lung tissues were homogenized and centrifuged. The 
TNF-α and IL-1β levels in the lung tissues were meas-
ured using commercially available ELISA kits (Keygen 
Biotech, Nanjing, China), according to the instructions 
provided by the manufacturer.
Detection of myeloperoxidase (MPO) activity
MPO activity, an indicator of polymorphonuclea (PMN) 
infiltration, was determined as previously described [20]. 
MPO activity was defined as the quantity of enzyme that 
degraded 1 mmol H2O2 at 37°C, and it was expressed as 
U/g wet tissue.
Statistical analysis
All statistical analyses were performed using SPSS 13.0 
(SPSS, Inc., IL, USA). Tests for normality and homogene-
ity of variances were performed. For normally distributed 
data, quantitative data are presented as mean ± standard 
deviation (SD). One-way analysis of variance (ANOVA) 
was used to test for differences among the seven groups. 
A statistical difference was considered when the P value 
was less than 0.05.
Results
Histological findings
Results obtained from light microscopy in the sham 
group (group S) showed complete structural integrity, 
clear alveolar space, and normal alveolar septum. In con-
trast, extensive pulmonary destruction, including mas-
sive inflammatory cell infiltration, obvious pulmonary 
hemorrhage, marked thickening of alveolar septum, and 
significant increase in the proportion of lung paren-
chyma, was observed in the group M. The rats in group 
M showed a higher pathological score than those in 
group S (P < 0.01). Dex pretreatment effectively reduced 
inflammatory cell infiltration and inhibited thickening 
of alveoli  septum in lung tissue, and this effect showed 
a dose–effect relationship. Rats pretreated with 10  µg/
kg or 50  µg/kg Dex had lower pathological scores than 
rats in group M (P  <  0.01). Interestingly, the protective 
effect of Dex could be blocked by the nonspecific α2-AR 
antagonist atipamezole or α2A-AR antagonist BRL-44408 
(P  <  0.01, group B1 or B3 vs. group D2) but not by the 
α2B/C-AR antagonist ARC-239 (P  >  0.05, group B2 vs. 
group D2; Figures 1, 2a).
Lung W/D weight ratio
The lung W/D weight ratio was used as an index of water 
accumulation in the lung. The lung water content of the 
right middle lobes in rats increase significantly after 
OALT (P < 0.01, group M vs. group S). Pretreatment with 
10 µg/kg or 50 µg/kg Dex remarkably reduced the water 
content of lung (P < 0.01, group D1 or D2 vs. group M). 
Treatment with atipamezole or BRL-44408, but not ARC-
239, weakened the protective effect of Dex against pul-
monary edema (P < 0.01, group B1 or B3 vs. group D2; 
Figure 2b).
Expression of TLR4 and phospho‑NF‑κB p65 subunit 
in lung tissues
The expression of TLR4 protein was measured by West-
ern blotting. TLR4 protein expression was significantly 
enhanced in lung tissues following OALT (P < 0.01, group 
M vs. group S). Pretreatment with Dex at 50 µg/kg down-
regulated the expression of TLR4 protein (P < 0.01, group 
D2 vs. group M), and this effect was reversed by treat-
ment with atipamezole or BRL-44408 (P < 0.05, group B1 
or B3 vs. group D2), but not by ARC-239 (P > 0.05, group 
B2 vs. group D2; Figure 3).
Cells stained positively for phospho-NF-κB were 
observed and counted under LSCM (magnification, 
400×). The expression of the phospho-NF-κB p65 
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subunit was significantly increased in rats after OALT 
(P < 0.01, group M vs. group S), suggesting an increased 
transport of activated NF-κB complexes into the 
nucleus. Pretreatment with 10  µg/kg or 50  µg/kg Dex 
down-regulated the elevated phospho-NF-κB p65 sub-
unit expression after OALT (P  <  0.01, group D1 or D2 
vs. group M), indicating that Dex pretreatment might 
inhibit the activation and nuclear transport of NF-κB 
proteins. The effect of Dex on the phospho-NF-κB p65 
subunit was diminished by treatment with atipamezole 
or BRL-44408 (P < 0.05, group B1 or B3 vs. group D2), 
but not ARC-239 (P > 0.05, group B2 vs. group D2; Fig-
ures 4, 5).
TNF‑α and IL‑1β concentrations and MPO activity in lung 
tissues
Production of pro-inflammatory factors in the lung is 
considered indicative of the severity of lung injury [21]. 
To evaluate the production of pro-inflammatory factors 
following OALT, TNF-α and IL-1β levels were exam-
ined by ELISA. The TNF-α and IL-1β  levels in lung tis-
sues were significantly higher in group M than in group 
Figure 1 Pathological changes in lung tissue in each group. Images (magnification, ×200) of representative sections from rat lungs stained with 
hematoxylin and eosin after harvest from group S (a), group M (b), group D1 (c), group D2 (d), group B1 (e), group B2 (f), and group B3 (g).
Figure 2 Pathological scores of lung injury (a) and lung wet-to-dry (W/D) weight ratio (b) in each group. The data are expressed as mean ± stand-
ard deviation (SD) (n = 8). ▲P < 0.01 vs. group S; ■P < 0.01 vs. group M; ◆P < 0.01 vs. group D2.
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S (P  <  0.05). Pretreatment with Dex appeared to have 
a stronger effect on reducing the levels of TNF-α and 
IL-1β (P < 0.05, group D1 or D2 vs. group M). However, 
these effects of Dex could be almost completely blocked 
by treatment with atipamezole or BRL-44408 (P  <  0.05, 
group B1 or B3 vs. group D2), but not by ARC-239 
Figure 3 The expression of TLR4 protein in lung tissues of different groups. a The levels of TLR4 protein were determined by Western blotting 
analysis. b Quantification of the Western blotting data and correction by reference to the value of GAPDH expression. The data are expressed as 
mean ± SD (n = 8). ▲P < 0.01; △P < 0.05 vs. group S; □P < 0.05 vs. group M; ◇P < 0.05 vs. group D2.
Figure 4 The expression of the phospho-NF-κB p65 subunit in lung tissues of different groups was detected by immunofluorescence staining 
under laser scanning confocal microscopy (magnification, ×400). a Group S; b, group M; c, group D1; d, group D2; e, group B1; f, group B2; and g, 
Group B3. Cells positive for phospho-NF-κB p65 were stained green, with the sections counterstained with 4,6-diamidino-2-phenylindole (DAPI) to 
visualize nuclei.
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(P > 0.05, group B2 vs. group D2). The MPO activity in 
lung tissues was consistent with TNF-α and IL-1β levels 
and showed a similar trend among the groups (Figure 6).
Discussion
This study investigated whether pretreatment with Dex 
has a protective effect against ALI in an OALT rat model. 
We found that Dex exerts protective effects against ALI 
following OALT, and this protection was mediated, at 
least in part, by the α2A-AR and was associated with the 
suppression of TLR4–NF-κB signaling.
In this study, we successfully established an OALT 
model according to a method used in previous studies 
[22]. This liver model can exactly imitate human patho-
physiologic conditions of liver transplantation. Patho-
logical changes in lung tissues following OALT included 
extensive pulmonary destruction such as massive 
inflammatory cell infiltration, obvious pulmonary hem-
orrhage, and marked alveolar septum thickening. More-
over, the pulmonary edema evaluated according to the 
W/D weight ratio was markedly increased after OALT 
as well. These results, taken together, provide defini-
tive evidence for ALI in the OALT model. We chose 8 h 
after transplantation as the observation point based on 
our previous research, which indicated that rats present 
the most serious damage to the lung at 8  h after liver 
transplantation.
Several triggering conditions, including hemorrhagic 
shock, endotoxin, trauma, burn injury, and ischemia–
reperfusion, contribute to ALI and exaggerate the inflam-
matory process of ALI [23–25]. NF-κB is an important 
nuclear transcription factor that upon activation, trans-
fers into the nucleus, amplifying inflammatory responses 
by promoting production of pro-inflammatory cytokines 
such as TNF-α, IL-6, and IL-8 [26, 27]. TLR4 plays an 
important role in the pathogenesis of ALI via activation 
of NF-κB signaling [7, 8, 24]. In a lipopolysaccharide 
(LPS)-induced ALI model, the gene expression level of 
pulmonary cytokines, such as TNF-α, IL-1β, and IL-6, 
is significantly increased in wild-type mice compared 
with TLR4-deficient mice [28]. A study by Lorenz et  al. 
found that TLR4-deficient murine macrophage cells are 
nonresponsive to stimulation by endotoxically active 
LPS of gram-negative bacteria, even under a high con-
centration [29]. Although direct blockade of TLR4 may 
potentially serve as an effective therapeutic strategy for 
acute pulmonary inflammation and ALI [30, 31], block-
ade of TLR4 must be applied with caution, because TLR4 
blockade is not beneficial for patients with sepsis [32]. 
Our findings revealed that the TLR4–NF-κB signaling 
pathway is involved in the pathogenesis of ALI after liver 
transplantation, as evidenced by increased levels of TLR4 
and phospho-NF-κB p65 subunit protein as well as pro-
inflammatory cytokines TNF-α and IL-1β in the injured 
lung.
Figure 5 The proportion of phospho-NF-κB subunit p65 positive 
cells in lung tissues of different groups. The cells were counted under 
laser scanning confocal microscopy (magnification, ×400). The data 
are expressed as mean ± standard deviation (SD) (n = 8). ▲P < 0.01; △P < 0.05 vs. group S; □P < 0.05 vs. group M; ◇P < 0.05 vs. group D2.
Figure 6 The concentrations of TNF-α (a) and IL-1β (b) and MPO activity (c) in lung tissues of different groups. The data are expressed as 
mean ± SD (n = 8). ▲P < 0.01; △P < 0.05 vs. group S; ■P < 0.01 vs. group M; ◆P < 0.01 vs. group D2.
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Dex has been reported to exert protective effects in 
various pulmonary conditions [15, 33]. Dex may directly 
suppress the immune response by modulating TLR4 
expression, which results in inhibition of inflammatory 
cytokine production. A study by Want et  al. demon-
strated that Dex might exert its protective effects against 
hydrogen sulfide-induced ALI through down-regula-
tion of matrix metalloproteinase (MMP)-2 and MMP-9 
expression [34]. It was also reported that pretreatment 
with Dex significantly reduces the lung injury caused by 
ischemia–reperfusion injury [15]. Our study found that 
pretreatment with Dex could cause a significant decrease 
in lung pathological scores and the lung W/D weight 
ratio, suggesting a protective effect of Dex on lung tissue. 
NF-κB activation was attenuated in rats treated with Dex, 
which was consistent with the changes in the expression 
of TLR4 as well as pro-inflammatory cytokines TNF-α 
and IL-1β in the lung tissue following OALT. Yang et al. 
[33] reported that Dex at the dose of 5.0 µg/kg per h sig-
nificantly attenuated the effects of ventilator-induced 
lung injury, which was mediated by the α2-AR.
Human and rat kidneys are reported to contain all 
three types of α2-ARs [35]. In this study, we used different 
α2-AR antagonists to elucidate the contribution of these 
α2-AR subtypes to the effects of Dex. Interestingly, the 
protective effects of Dex could be blocked by the nonspe-
cific α2-AR antagonist atipamezole or α2A-AR antagonist 
BRL-44408, but not by the α2B-AR antagonist ARC-239, 
suggesting these effects of Dex were mediated, at least in 
part, by the α2A-AR. Our results are consistent with pre-
vious findings that Dex provides potent neuroprotection 
mediated via the α2A-AR subtype in a model of perina-
tal excitotoxic brain injury [36]. The exact mechanism 
by which Dex exerts its protective effects via the α2A-AR 
requires further investigation.
Conclusions
Dex exerts protective effects against ALI following OALT, 
and this protection is associated with the suppression of 
TLR4–NF-κB signaling, which may explain the inhibitory 
effect of Dex on the production of pro-inflammatory fac-
tors TNF-α and IL-1β. These effects of Dex were medi-
ated by the α2A-AR. Thus, pretreatment with Dex may be 
a useful method for reducing the lung damage caused by 
liver transplantation.
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